Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$3.68 +10.5%	$2.47	$1.89 ▼ $4.12	$993.75M	0.36	3.27 million shs	7.94 million shs
AKRO Akero Therapeutics	$53.92 -0.2%	$46.52	$21.02 ▼ $58.40	$4.31B	-0.16	1.03 million shs	4.37 million shs
DICE DICE Therapeutics	$47.55	$47.31	$15.08 ▼ $47.90	$2.27B	1.03	1.03 million shs	N/A
HRMY Harmony Biosciences	$32.06 +0.4%	$32.71	$26.47 ▼ $41.61	$1.83B	0.87	625,035 shs	545,420 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+10.51%	+17.95%	+86.80%	+52.07%	+31.90%
AKRO Akero Therapeutics	-0.20%	-2.67%	+16.31%	+24.56%	+126.08%
DICE DICE Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
HRMY Harmony Biosciences	+0.41%	-1.26%	-6.18%	-3.46%	+6.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.1414 of 5 stars	3.4	1.0	0.0	0.0	2.3	3.3	0.0
AKRO Akero Therapeutics	3.6239 of 5 stars	3.5	1.0	0.0	4.7	1.8	1.7	0.0
DICE DICE Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	4.7414 of 5 stars	4.6	1.0	0.0	0.0	2.8	3.3	4.4

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.75	Moderate Buy	$8.33	126.45% Upside
AKRO Akero Therapeutics	3.00	Buy	$82.50	53.00% Upside
DICE DICE Therapeutics	0.00	N/A	N/A	N/A
HRMY Harmony Biosciences	3.13	Buy	$53.63	67.26% Upside

Current Analyst Ratings Breakdown

Latest AKRO, HRMY, DICE, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/16/2025	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $10.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
4/16/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$4.00 ➝ $5.00
4/8/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
4/8/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	38.09	N/A	N/A	$3.58 per share	1.03
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
DICE DICE Therapeutics	$1.13M	2,008.50	N/A	N/A	$10.86 per share	4.38
HRMY Harmony Biosciences	$714.73M	2.58	$2.96 per share	10.84	$11.56 per share	2.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/5/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
DICE DICE Therapeutics	-$83.89M	-$2.34	N/A	N/A	N/A	N/A	-22.01%	-20.79%	N/A
HRMY Harmony Biosciences	$145.49M	$2.62	12.24	10.31	0.47	20.53%	24.32%	15.92%	8/5/2025 (Estimated)

Latest AKRO, HRMY, DICE, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
DICE DICE Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
AKRO Akero Therapeutics	0.03	16.80	16.80
DICE DICE Therapeutics	N/A	25.88	32.44
HRMY Harmony Biosciences	0.22	3.67	3.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
AKRO Akero Therapeutics	N/A
DICE DICE Therapeutics	N/A
HRMY Harmony Biosciences	86.23%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
AKRO Akero Therapeutics	7.07%
DICE DICE Therapeutics	4.90%
HRMY Harmony Biosciences	23.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
DICE DICE Therapeutics	71	47.73 million	45.39 million	Not Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable

AKRO, HRMY, DICE, and ABCL Headlines

Recent News About These Companies

First Week of August 15th Options Trading For Harmony Biosciences Holdings (HRMY) - Nasdaq

June 25 at 12:35 AM | nasdaq.com

Needham Reiterates a Buy Rating on Harmony Biosciences (HRMY)

June 24 at 7:35 PM | msn.com

Analysts Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Target Price at $53.63

June 24 at 1:37 AM | americanbankingnews.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Exchange Traded Concepts LLC Takes Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 20, 2025 | marketbeat.com

Harmony Biosciences obtains favorable settlement in litigation over generic Wakix

June 19, 2025 | drugstorenews.com

SG Americas Securities LLC Has $1.17 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 18, 2025 | marketbeat.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Significant Increase in Short Interest

June 17, 2025 | marketbeat.com

Harmony Biosciences (NASDAQ:HRMY) Trading Down 4.5% - Should You Sell?

June 12, 2025 | marketbeat.com

77,867 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Purchased by CX Institutional

June 12, 2025 | marketbeat.com

Millennium Management LLC Has $218,000 Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on HRMY FY2026 Earnings

June 11, 2025 | marketbeat.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by California State Teachers Retirement System

June 10, 2025 | marketbeat.com

Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory

June 9, 2025 | insidermonkey.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Bridge City Capital LLC

June 9, 2025 | marketbeat.com

Harmony Biosciences Holdings (HRMY) Shares Cross Below 200 DMA

June 7, 2025 | nasdaq.com

Harmony Biosciences settles generic drug litigation, strengthens patent

June 6, 2025 | finance.yahoo.com

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

June 5, 2025 | businesswire.com

Hennion & Walsh Asset Management Inc. Boosts Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 5, 2025 | marketbeat.com

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | businesswire.com

GAMMA Investing LLC Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKRO, HRMY, DICE, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$3.68 +0.35 (+10.51%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$3.94 +0.26 (+7.07%)

As of 08:18 AM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Akero Therapeutics NASDAQ:AKRO

$53.92 -0.11 (-0.20%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$53.96 +0.05 (+0.08%)

As of 08:00 AM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

DICE Therapeutics NASDAQ:DICE

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Harmony Biosciences NASDAQ:HRMY

$32.06 +0.13 (+0.41%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$32.08 +0.02 (+0.08%)

As of 06/24/2025 05:59 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time